Target Identification and Validation
* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.
Targeted protein degradation has changed what counts as a viable drug target. Instead of asking whether a protein has a pocket suitable for inhibition, PROTACs, molecular glues, and lysosomal degraders ask a different question: can this protein be selectively removed, and does removing it actually change disease biology? That shift makes target identification and validation the first and most consequential decision point in a degradation program. BOC Sciences provides integrated TPD target identification and validation services covering target prioritization, functional validation, degradability assessment, subcellular localization analysis, protein expression profiling, and E3 ligase compatibility evaluation. Working from your disease hypothesis, our team combines bioinformatics, multi-omics, functional genomics, and chemical probe strategies to establish whether a target is disease-relevant, degradable, and worth advancing into ubiquitin-proteasome-based degradation technology development or an alternative degradation route.
Request a Consultation Explore ServicesServices
BOC Sciences Target Identification and Validation Services for TPD
Every degradation program begins with a target that has to earn its place. Our service modules are built to answer the questions that determine whether a protein deserves further investment: is it disease-relevant, is it functionally validated, and can it be degraded selectively by a mechanism that makes sense for the biology.
Target Identification and Prioritization
We integrate disease genetics, pathway mapping, expression data, and curated literature evidence to assemble a candidate target list, then rank targets by disease relevance, dependency, and degradation feasibility. Domain architecture, surface accessibility, and known ligand availability are reviewed through target protein services so that prioritization reflects both biology and degrader chemistry.
Target Functional Validation
Target relevance is confirmed through genetic and pharmacological perturbation, including CRISPR knockout, RNA interference, degron systems, and target-specific chemical probes. Phenotypic readouts such as proliferation, apoptosis, pathway biomarkers, and transcriptional signatures reveal whether loss of the target produces the expected disease-relevant effect, with PROTAC activity assay formats used to link target engagement to downstream biology.
Target Degradability Assessment
Not every disease-relevant protein can be degraded. We evaluate lysine distribution, disordered regions, ternary complex geometry, and E3 ligase accessibility to estimate degradability before synthesis resources are committed, and confirm the prediction with degradation ability assay readouts including DC50, Dmax, and degradation kinetics.
Subcellular Localization Analysis
Protein function and degradation accessibility are strongly compartment-dependent. We map target distribution across nuclear, cytoplasmic, membrane, and organelle compartments using imaging, biochemical fractionation, and reporter systems, then connect the observed localization to the E3 ligase systems most likely to reach the target in a productive way.
Target Protein Expression Profiling
Absolute and relative expression across cell lines, primary models, and disease-relevant tissues determines both therapeutic opportunity and normal-tissue considerations. We profile mRNA and protein abundance, tissue distribution, and cell-type heterogeneity to support selectivity-oriented target decisions and to identify models that faithfully represent the intended disease setting.
E3 Ligase Compatibility Assessment
The choice of E3 ligase recruiter shapes both degradation efficiency and selectivity. We assess CRBN, VHL, IAP, MDM2, and alternative ligase systems for expression, subcellular overlap with the target, and substrate profile, supported by E3 ubiquitin ligase activity assay formats that quantify ligase engagement and ubiquitin transfer.
Need to Confirm Whether Your Target Is Degradable?
From functional validation to degradability assessment and E3 ligase compatibility screening, we help you decide which targets are worth pursuing.
Target Types
TPD Target Identification and Validation by Target Type
Target classes differ in how they should be identified and how their degradation should be verified. An enzyme target is judged by catalytic output, a transcription factor by the transcriptional network it controls, and a membrane protein by trafficking rather than proteasomal turnover. The table below summarizes the identification and validation logic we apply to each major target class.
| Target Type | Identification Focus | Validation Focus | Typical Technologies |
|---|---|---|---|
| Enzyme Targets (kinases such as CDK, BTK, EGFR, and ALK; proteases; epigenetic enzymes such as HDAC, EZH2, and BRD4) | Membership of a disease-driving pathway, activating mutations or overexpression, and a defined catalytic function | Whether degradation affects enzyme activity, whether it outperforms simple inhibition by removing scaffolding function, and whether turnover depends on the proteasome | Enzymatic activity assays, phospho-substrate detection, DC50 and Dmax determination, rescue experiments, and PROTACs targeting protein kinases |
| Transcription Factor Targets (MYC, STAT3, IRF4, E2F, androgen receptor, estrogen receptor) | Whether the factor is a core transcriptional driver and whether tumors or immune cells are highly dependent on it | Whether degradation reshapes downstream gene expression and the transcriptional network rather than only lowering protein level, and whether the target is conventionally difficult to drug | RNA-seq and qPCR, ChIP-seq and CUT&RUN, reporter systems, downstream proteomics, and PROTACs targeting nuclear receptors |
| Scaffolding Protein Targets (IRAK4, TRAF6, RIPK1, β-catenin, and other adaptor proteins) | Whether disease is driven by protein-protein interactions rather than catalytic activity, and whether the protein acts as a structural platform | Whether degradation is more effective than inhibition, whether complex formation is blocked, and whether assembly of signaling complexes is disrupted | Co-immunoprecipitation and interactome mapping, complex structural analysis, pathway protein detection, and in silico protein-protein interactions prediction |
| Membrane Protein Targets (GPCRs, receptor tyrosine kinases such as EGFR and HER2, ion channels, transporters) | Cell-surface abundance, disease association, and whether the protein is accessible to extracellular recognition | Whether the degradation route depends on lysosomal rather than proteasomal machinery, and whether internalization, recycling, or membrane trafficking is altered | Flow cytometry, internalization assays, surface protein biotinylation, immunofluorescence, and membrane protein degradation technology development |
| Protein Complex Component Targets (BET family proteins BRD2/3/4, Polycomb components, SWI/SNF subunits, CRL components) | Whether the protein is a critical node whose removal collapses the function of an entire complex | Whether complex stability is affected, whether synthetic lethal effects emerge, and whether assembly and recruitment of the complex are disrupted | Complex immunoprecipitation, proteomics, structural biology, dependency screening, and PROTACs targeting BET proteins |
| Undruggable Targets (MYC, selected RAS variants, β-catenin, interaction surfaces without defined pockets) | Absence of a conventional binding pocket, reliance on protein-protein interaction or allosteric mechanisms, and strong dependency on a specific disease context | Whether a bindable site can be found even without a functional pocket, whether E3 ligase recruitment enables productive degradation, and whether a therapeutic window exists | Chemoproteomics, structure prediction, fragment screening, molecular glue screening, rescue experiments, and PROTAC targeting KRAS |
| Mutant and Fusion Protein Targets (BCR-ABL, EML4-ALK, mutant EGFR, AR-V7) | Whether the mutation or fusion drives disease and whether the altered protein is a better degradation substrate than the wild-type form | Whether mutant-selective degradation is achieved, whether wild-type protein is spared, and whether resistance mutations are overcome | Mutation-specific antibody detection, isogenic cell lines, proteome-wide selectivity analysis, resistance models, and PROTAC targeting ALK |
| Viral and Pathogen-Associated Targets (viral replication proteins, structural proteins, host dependency factors) | Whether the protein is essential to the pathogen lifecycle and whether host degradation machinery can be redirected toward it | Whether degradation suppresses replication, whether assembly or release is impaired, and whether host proteins are largely unaffected | Infection models, viral titer readouts, host proteomics, immunofluorescence, and confocal imaging |
Modalities
Target Identification and Validation for Different TPD Modalities
Degrader format matters as much as target class. A PROTAC depends on ternary complex formation and the ubiquitin-proteasome system, a molecular glue depends on a glueable protein surface, and a lysosomal degrader depends on internalization and trafficking. Each modality therefore carries its own eligibility criteria and its own validation readout set.
PROTAC Target Identification and Validation
PROTAC programs require an intracellular target, an accessible lysine, a linker geometry that supports a productive ternary complex, and an E3 ligase expressed in the relevant cell type. Our validation package reflects that logic.
- Ternary complex formation, hook-effect behavior, and lysine site mapping
- DC50, Dmax, ubiquitination, and proteasome-dependence rescue
- Ligase knockdown rescue and warhead competition controls
See our PROTAC degradation technology development capabilities for the downstream workflow.
Molecular Glue Degrader Target Identification and Validation
Molecular glues are monovalent and do not require a known ligand or pocket. Identification therefore starts from a phenotypic or screening signal, and validation focuses on whether a neo-interaction between the E3 ligase and the target is genuinely induced.
- CRBN dependence and neo-substrate profiling across the proteome
- Glue interface and degron mutagenesis to confirm the induced interaction
- Ternary complex characterization of the ligase-glue-target assembly
Our molecular glue technology development platform supports screening and mechanism confirmation.
LYTAC Target Identification and Validation
LYTACs redirect extracellular and membrane proteins to the lysosome through receptors such as the cation-independent mannose-6-phosphate receptor. Eligibility is therefore defined by surface residency and internalization rather than by lysine accessibility.
- Surface abundance and internalization rate of the target protein
- Colocalization with lysosomal markers and lysosomal-blockade rescue
- Trafficking and recycling analysis after degradation
Explore LYTAC degradation technology development for extracellular targeting strategies.
AbTAC Target Identification and Validation
Antibody-based degraders use a bispecific format that brings a membrane-bound E3 ligase and a cell-surface target together, so the target must be accessible from outside the cell and the complex must be internalized.
- Cell-surface epitope accessibility and antibody binding confirmation
- Internalization kinetics and lysosomal delivery of the complex
- Verification that degradation is independent of the proteasome
Our AbTAC degradation technology development team designs the validation route for antibody-format degraders.
KineTAC Target Identification and Validation
KineTACs use cytokine receptors and chemokine scavenging receptors as delivery vehicles, which means the target profile must be evaluated together with the receptor pathway used for transport.
- Receptor expression and internalization capacity in the disease model
- Target clearance kinetics and surface protein recovery
- Pathway-specific readouts to separate target loss from receptor effects
Discuss your construct with our KineTAC technology development group to define the right validation endpoints.
AUTAC, ATTEC, and AUTOTAC Target Identification and Validation
Autophagy-based degraders route targets to the lysosome through autophagic machinery, which makes them attractive for aggregate-prone proteins and membrane proteins that are difficult to address with E3 ligase recruiters.
- Autophagic flux readouts including LC3-II conversion and p62 turnover
- Dependence on ATG5 or ATG7 to confirm autophagy-mediated clearance
- Aggregate clearance and lysosomal blockade rescue experiments
Our AUTAC degradation technology development platform covers autophagy-directed degradation strategies.
Not Sure Which Degradation Modality Fits Your Target?
Talk to our scientists about PROTAC, molecular glue, LYTAC, or autophagy-based strategies and the validation path each one requires.
Why It Matters
Why Target Identification and Validation Is Critical for PROTAC Success?
Selecting PROTAC-Compatible Targets Early
Degradability is not distributed evenly across the proteome. Screening for lysine availability, accessible surface regions, and compatible E3 ligases at the start of a program prevents teams from investing months of chemistry into targets that will never degrade well, and it connects directly to PROTAC design for target proteins.
Reducing Late-Stage Project Attrition
Degradation programs rarely fail because a compound cannot be made. They fail when the biology behind the target does not hold up. Validating disease relevance and functional consequence early is the most reliable way to avoid carrying an unsupported hypothesis through lead optimization.
Aligning Target Biology with Degradation Mechanism
A target may be removed efficiently and still produce no useful effect if the degradation mechanism is incompatible with how the protein works. Confirming ternary complex productivity and downstream pathway response through PROTAC ternary complex assay formats keeps mechanism and biology aligned.
Strengthening Disease-Drug-Target Evidence Chains
A defensible target package links genetic evidence, functional dependency, expression data, and degradation data into a single chain of reasoning. That chain is what allows a program to survive internal review, partner evaluation, and changes in project leadership.
Applications
Applications of TPD Target Identification and Validation
Target Selection for PROTAC Discovery
Build a ranked, evidence-supported target list before committing to PROTAC design services, so that synthetic effort is directed toward proteins with both disease relevance and realistic degradation feasibility.
Target Assessment for Molecular Glue Degraders
Evaluate whether a target presents a glueable surface and whether a phenotypic screening signal can be traced back to a defined E3 ligase interaction, giving molecular glue programs a mechanistic anchor rather than a purely observational one.
Functional Validation of Difficult-to-Inhibit Proteins
Establish whether removing a protein that lacks a druggable pocket produces a measurable therapeutic effect, and whether that effect is superior to what partial inhibition or pathway modulation could achieve.
Investigation of Cell-Type-Specific Degradation Resistance
Determine why the same target degrades efficiently in one cell model and poorly in another, by comparing E3 ligase expression through PROTAC selectivity evaluation, subcellular localization, and target complex context across models.
Workflow
Our TPD Target Identification and Validation Workflow
01
Project Requirements and Target Biology Review
We review your disease hypothesis, target family, prior data, intended degradation modality, and preferred cell models to define clear go and no-go questions before any experiment is designed.
02
Candidate Target Identification and Prioritization
Bioinformatics, expression databases, and dependency datasets are combined through PROTAC design based on bioinformatics to generate and rank candidate targets by disease linkage and degradation feasibility.
03
Functional Perturbation and Phenotypic Validation
CRISPR knockout, RNA interference, degron systems, and chemical probes are used to confirm that losing the target produces the expected phenotype, with PROTAC in vitro evaluation providing a degradation-linked comparison point.
04
Target Expression and Subcellular Localization Profiling
Protein and mRNA abundance, tissue distribution, and compartment-specific localization are mapped across disease-relevant and control models to confirm that the target is present where degradation is expected to occur.
05
Degradability and Degradation Mechanism Assessment
Lysine mapping, ternary complex feasibility, and ubiquitin transfer are evaluated, supported by protein ubiquitination services that confirm the target is genuinely routed through the intended degradation pathway.
06
Integrated Data Analysis and Target Selection
BOC Sciences consolidates genetics, expression, localization, functional, and degradability data into a structured report that ranks targets, flags remaining risks, and recommends the most appropriate degradation modality for each candidate.
Which Stage of Your TPD Target Validation Needs Support?
Whether you are identifying candidate targets, validating biological functions, analyzing protein expression and localization, or assessing degradability, BOC Sciences can provide tailored support at your current project stage. Tell us where you are, and we will help you plan the next steps.
Why Us
Why Choose BOC Sciences for TPD Target Identification and Validation?
Multiple Complementary Validation Methods
Target decisions are stronger when they do not rest on a single assay. We combine genetic perturbation, protein-level measurement, degradation kinetics, and TR-FRET in vitro ubiquitylation assay readouts so that each conclusion is supported from more than one direction.
Customized Assays for Diverse Protein Targets
Enzymes, transcription factors, scaffolding proteins, membrane proteins, and complex components all require different readouts. Assay panels are designed around the biology of your specific target rather than applied from a fixed menu.
Disease-Relevant Cellular Models
Expression, dependency, and degradation behavior can differ sharply between immortalized lines and disease-representative models. We help select and characterize models that preserve the biology your program actually depends on.
Data-Driven Target Prioritization and Research Guidance
Beyond reporting results, we translate them into practical direction. Insights from structures and mechanisms of PROTAC research are used to advise on target ranking, modality choice, and the next round of experimental design.
Case Study
Client Success Stories: Target Identification and Validation
Project Background
A European oncology-focused biotechnology company was evaluating MYC as a degradation target for a solid tumor research program. MYC is a bHLH-LZ transcription factor that drives proliferation through a broad transcriptional network, and it lacks the defined binding pocket needed for conventional inhibition. The client had confirmed strong MYC dependency in two tumor models but did not know whether MYC degradation was technically achievable or whether removing the protein would produce a usable phenotypic effect rather than general toxicity.
Technical Challenges
MYC is predominantly nuclear, intrinsically disordered across much of its sequence, and has a short half-life, which makes degradation measurements noisy and hard to interpret. The client also lacked a validated ligand for the target, so the entry point for a degrader was unclear, and there was no way to tell whether reduced proliferation after perturbation reflected MYC loss or a nonspecific effect.
BOC Sciences Solutions
- Dependency and Expression Confirmation: We profiled MYC mRNA and protein levels across the client's tumor models and normal epithelial controls, and confirmed that expression and dependency were both substantially elevated in the tumor setting.
- Subcellular Localization Mapping: Imaging and fractionation confirmed a predominantly nuclear localization, which directed the evaluation toward E3 ligase systems that efficiently reach nuclear substrates.
- Genetic Functional Validation: CRISPR knockout, RNA interference, and a degron-based degradation system were compared side by side, with RNA-seq used to determine whether transcriptional output collapsed in a way that matched the observed proliferation phenotype.
- Degradability and Modality Assessment: We evaluated lysine distribution and accessible surface regions on MYC, assessed ternary complex feasibility with nuclear-resident ligases, and compared PROTAC and molecular glue entry strategies for the target.
Project Outcomes
BOC Sciences confirmed that MYC is functionally validated in the client's tumor models and that degradation of the transcription factor produces a measurable collapse in proliferative transcriptional programs rather than only a reduction in protein level. Among the modalities evaluated, a CRBN-based PROTAC targeting c-Myc approach offered the most tractable entry point, with a nuclear-accessible ligase and a compatible lysine region identified on the target surface. The client was able to move into degrader design with a validated functional rationale, a defined modality, and a clear set of downstream transcriptional markers for measuring the effect of degradation.
Project Background
A US-based pharmaceutical research team was assessing IRAK4 as a degradation target in tumor signaling research. IRAK4 is a kinase, but a large part of its disease contribution comes from scaffold activity that organizes the Myddosome signaling complex. The client had observed that catalytic inhibition only partially suppressed downstream signaling and wanted to determine whether removing the protein would achieve what inhibition could not.
Technical Challenges
Separating the catalytic function of IRAK4 from its scaffolding role required readouts that inhibition studies alone could not provide. The client also needed to know whether IRAK4 degradation would be strong enough in the relevant tumor models and whether complex-level effects would be reproducible across cell backgrounds.
BOC Sciences Solutions
- Complex-Level Target Characterization: Co-immunoprecipitation and interactome analysis were used to map IRAK4 complex components and to define which interactions depended on the scaffolding function rather than catalytic activity.
- Head-to-Head Inhibition versus Degradation Comparison: Catalytic inhibition and genetic ablation were compared within the same model system to quantify how much additional pathway suppression could be achieved by removing the protein.
- Degradability Assessment: Lysine accessibility, surface context, and ligase compatibility were evaluated across several E3 ligase systems, and degradation feasibility was confirmed before any degrader chemistry was initiated.
- Selectivity and Model Screening: Expression and degradation behavior were profiled across tumor models and control cells to identify backgrounds where IRAK4 degradation would be most informative.
Project Outcomes
The comparison showed that IRAK4 degradation suppressed downstream signaling more effectively than catalytic inhibition alone, consistent with a meaningful scaffolding contribution that only protein removal could address. BOC Sciences identified a CRBN-based PROTAC targeting IRAK4 strategy as the most promising route, defined a set of tumor models with consistent degradation behavior, and provided the client with a validated rationale for prioritizing IRAK4 degradation over further inhibitor optimization in this program.
Frequently Asked Questions (FAQ)
How Do You Prioritize Targets for TPD Discovery Projects?
Promising TPD targets should be selected using more than differential expression or pathway association. A strong candidate shows a reproducible connection to a disease-relevant phenotype, supported by genetic dependency data, functional perturbation studies, and protein-level evidence. Researchers should also examine which cell types depend on the target, whether removing the entire protein offers advantages over inhibiting a single activity, and whether a suitable degradation pathway can reach the protein. Ligandability, protein turnover, subcellular localization, and potential selectivity concerns further influence feasibility. BOC Sciences integrates these findings to rank candidate targets, identify evidence gaps, and recommend focused validation experiments before committing resources to degrader design.
How Can We Distinguish Target Degradation from Indirect Effects?
Loss of target protein signal alone does not establish an on-target functional mechanism. Validation should compare target abundance with downstream pathway activity and cellular phenotypes across matched concentration-response and time-course experiments. Genetic knockdown or knockout can determine whether target depletion reproduces the observed effect, while rescue experiments can help establish causal dependence. Non-degrading analogs, appropriate target-binding controls, and orthogonal proteomic measurements help distinguish induced degradation from binding-mediated inhibition or unrelated protein loss. For ubiquitin-proteasome-dependent degraders, pathway perturbation provides additional mechanistic evidence when interpreted alongside target engagement and ubiquitination data. The strongest conclusions come from multiple independent methods producing a consistent explanation of the observed biological response.
What Determines Whether a Target Is Suitable for PROTACs?
PROTAC suitability requires both a meaningful biological rationale and an achievable degradation mechanism. A target-binding ligand must engage an accessible region of the protein, but binding affinity alone is insufficient. Productive degradation also depends on compatible E3 ligase recruitment, favorable ternary complex formation, accessibility for ubiquitination, cellular colocalization, and a functional proteasome pathway. Target abundance, protein resynthesis, cellular permeability, and context-dependent protein interactions can influence degradation efficiency. BOC Sciences can combine binding and ternary complex studies with cellular degradation assays to assess degradation potency, maximum target depletion, and recovery kinetics. These measurements can then be connected with pathway activity and phenotypic responses to determine whether a target is suitable for further PROTAC development.
How Does Target Validation Differ Between TPD Modalities?
Each TPD modality requires evidence that matches the degradation machinery it recruits. PROTAC programs focus on target binding, E3 recruitment, ternary complex formation, ubiquitination, and proteasome-dependent protein loss. Molecular glue projects often begin with the identification of newly recruited substrates, followed by confirmation of the responsible E3 ligase and degradation selectivity. LYTAC, AbTAC, and KineTAC strategies require analysis of extracellular or cell-surface accessibility, receptor expression, internalization, and lysosomal trafficking. Autophagy-based approaches introduce additional questions about cargo recognition, autophagic machinery, and autophagic flux. BOC Sciences can tailor target profiling, pathway perturbation experiments, imaging methods, and functional readouts to the selected degradation strategy, helping researchers establish a suitable validation framework for each modality.
How Does BOC Sciences Implement TPD Target Validation Services?
BOC Sciences provides flexible target identification and validation services tailored to each client's research objectives, target characteristics, and project stage. The process begins with a technical consultation and review of available information, such as candidate target profiles, disease-relevant models, omics datasets, or preliminary degradation results. Our scientists identify key evidence gaps and develop a customized experimental strategy covering target prioritization, functional validation, protein expression profiling, subcellular localization, and degradability assessment. Clients can engage BOC Sciences at any stage of their research, whether they need a specific assay or an integrated validation program. Following experimental evaluation, we provide structured data analysis, target feasibility insights, and recommendations to guide subsequent TPD research and degrader development decisions.
Testimonials
Client Testimonials on TPD Target Identification and Validation
Clearer Target Rationale for PROTAC Programs
"We had a target we believed in but no defensible evidence package behind it. BOC Sciences pulled together expression, localization, and functional data into a rationale our review committee could actually act on, and it changed how we framed the whole program."
— Dr. Edwards, Head of Discovery Biology at a European Biotech Firm
Confident Go / No-Go Decision Support
"We needed to decide whether to keep two of our four candidate targets. The degradability and E3 ligase compatibility data were decisive, and the team told us plainly which targets were unlikely to work rather than hedging."
— Ms. Cook, Project Director at a US-Based Pharmaceutical Research Group
Integrated Multi-Omics and Functional Evidence
"What stood out was the integration. Expression profiling, subcellular localization analysis, and functional perturbation results were interpreted together instead of being handed back as separate reports, and that made the conclusions far more reliable."
— Dr. Ramos, Translational Research Lead at a German Oncology-Focused Institute
Practical Bridge from Validation to PROTAC Design
"The validation work did not stop at the biology. Their recommendations on which ligase system to use and where to attach a linker gave our chemistry team a concrete starting point for the next degrader series."
— Dr. Lange, Medicinal Chemistry Lead at a UK-Based Research Organization
* PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
BOC Sciences Support
Please contact us with any specific requirements and we will get back to you as soon as possible.
